Innovation Kyoto 2016 Investment Limited Partnership ("KYOTO-icap No.1 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto iCAP") (Head office: Sakyo-ku, Kyoto; President: Koji Murota) as unlimited liability partner, has recently made an investment in Oligogen Co. (Head office: Sakyo-ku, Kyoto; President: Tsuneo Kido), a venture company that utilizes research results from Kyoto University.

○Oligogen Investment Execution
OligoGenie is a venture company whose main business is the research and development of novel therapies for nervous system diseases. The company's president, Dr. Kido, is a neurologist from the Kyoto University School of Medicine. As a result of his research activities in the United States and other countries, he discovered new neural stem cells and named them "OligoGenie.

Nerve activity requires axons that transmit electrical signals and the insulating myelin sheath that surrounds them. OligoGenie is characterized by its extremely high differentiation potential into oligodendrocytes that form this myelin sheath. OligoGenie is currently working on the commercialization of therapeutic drugs targeting various intractable diseases caused by abnormalities or damage to oligodendrocytes by taking advantage of OligoGenie's characteristics.

Kyoto iCAP highly evaluated Oligogen's management philosophy of bringing novel therapeutic drugs to patients suffering from intractable diseases and its research and development capabilities in discovering novel neural stem cells, and together with Nissei Capital Inc. agreed to a private placement of 75 million yen in total and made a 25 million yen investment.

Overview of Oligogen Corporation

Establishment	August 2015
Business	Development of novel therapeutic drugs for neurological diseases
Head Office Location	Sakyo-ku, Kyoto
President & CEO	Tsuneo Kido